JP2023058608A5 - - Google Patents

Download PDF

Info

Publication number
JP2023058608A5
JP2023058608A5 JP2023017816A JP2023017816A JP2023058608A5 JP 2023058608 A5 JP2023058608 A5 JP 2023058608A5 JP 2023017816 A JP2023017816 A JP 2023017816A JP 2023017816 A JP2023017816 A JP 2023017816A JP 2023058608 A5 JP2023058608 A5 JP 2023058608A5
Authority
JP
Japan
Prior art keywords
protein
subject
biomarkers
hae
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023017816A
Other languages
English (en)
Japanese (ja)
Other versions
JP7412616B2 (ja
JP2023058608A (ja
Filing date
Publication date
Priority claimed from JP2019514252A external-priority patent/JP7225089B2/ja
Application filed filed Critical
Publication of JP2023058608A publication Critical patent/JP2023058608A/ja
Publication of JP2023058608A5 publication Critical patent/JP2023058608A5/ja
Priority to JP2023218832A priority Critical patent/JP7693788B2/ja
Application granted granted Critical
Publication of JP7412616B2 publication Critical patent/JP7412616B2/ja
Priority to JP2025094023A priority patent/JP2025124852A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023017816A 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー Active JP7412616B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023218832A JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395712P 2016-09-16 2016-09-16
US62/395,712 2016-09-16
US201762518492P 2017-06-12 2017-06-12
US62/518,492 2017-06-12
JP2019514252A JP7225089B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019514252A Division JP7225089B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023218832A Division JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー

Publications (3)

Publication Number Publication Date
JP2023058608A JP2023058608A (ja) 2023-04-25
JP2023058608A5 true JP2023058608A5 (https=) 2023-07-19
JP7412616B2 JP7412616B2 (ja) 2024-01-12

Family

ID=59974881

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019514252A Active JP7225089B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023017816A Active JP7412616B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2023218832A Active JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A Pending JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019514252A Active JP7225089B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患のタンパク質バイオマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023218832A Active JP7693788B2 (ja) 2016-09-16 2023-12-26 接触活性化系に関連する疾患のタンパク質バイオマーカー
JP2025094023A Pending JP2025124852A (ja) 2016-09-16 2025-06-05 接触活性化系に関連する疾患のタンパク質バイオマーカー

Country Status (12)

Country Link
US (2) US11815516B2 (https=)
EP (1) EP3513196B1 (https=)
JP (4) JP7225089B2 (https=)
KR (3) KR102806918B1 (https=)
CN (2) CN109716138B (https=)
AU (3) AU2017325983B2 (https=)
BR (1) BR112019005179A2 (https=)
CA (1) CA3037154A1 (https=)
CO (1) CO2019002599A2 (https=)
IL (2) IL265195B2 (https=)
MX (2) MX2019002932A (https=)
WO (1) WO2018053244A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001174463A (ja) * 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
JP4399593B2 (ja) * 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007059966A1 (en) * 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
US8883153B2 (en) * 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9102942B2 (en) * 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
JP2011226882A (ja) * 2010-04-19 2011-11-10 Kitasato Institute 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US20130102486A1 (en) * 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
EP2946206B1 (en) * 2013-01-20 2019-01-09 Dyax Corp. Evaluation, assays and treatment of pkal-mediated disorders
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
JP6757252B2 (ja) * 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
AU2015209481C1 (en) * 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EP3132053B1 (en) * 2014-04-15 2020-09-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Differential diagnosis of eczema and psoriasis
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system

Similar Documents

Publication Publication Date Title
Larsson et al. The effects of age and gender on plasma levels of 63 cytokines
Cehofski et al. Aqueous fibronectin correlates with severity of macular edema and visual acuity in patients with branch retinal vein occlusion: a proteome study
CN109716137B (zh) 用于与接触活化系统相关的疾病的代谢产物生物标记
JP2023058608A5 (https=)
JP2016513253A (ja) 急性呼吸促迫症候群(ards)関連バイオマーカーを測定する方法、患者におけるardsの進行および治療をモニターする方法
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
JP6732914B2 (ja) トリプトファニルtRNA合成酵素を利用した感染症又は感染合併症の診断用組成物と診断マーカー検出方法
Shin et al. Identification of ganglioside GM 2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes
JP6645981B2 (ja) サーマルシフトアッセイを使用して薬物反応の減少の指標となるバイオマーカーを識別するための方法
CN101023356A (zh) 诊断肝纤维化的方法
Matsumoto et al. Proteomic comparison between abdominal and thoracic aortic aneurysms
EP3189337A1 (en) Biomarker signatures for lyme disease and methods of use thereof
Dong et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis
US20160223537A1 (en) Identification of novel biomarkers of flares of systemic lupus erythematosus
KR20040012854A (ko) 미생물의 동정 방법
KR102681006B1 (ko) 뇌의 레닌-안지오텐신 시스템 인자를 이용한 알츠하이머병의 진단 방법
SI24638A (sl) Fluorometrična imunska metoda za določanje protiteles proti dvojnoverižni DNA
US20140051598A1 (en) Diagnostic biomarker to predict women at risk for preterm delivery
Korte et al. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus
JP2019529906A5 (https=)
Barenghi et al. Saliva: challenges, possibilities, and limits of the diagnostic use Part 2–pre-analytical and analytical aspects
JP5876673B2 (ja) 精神障害の診断方法および診断薬キット
US20130115638A1 (en) Method and rapid test for determining the fertility of sperm
JP7307479B2 (ja) IgA腎症診断用キット
JP2011107116A (ja) 脳梗塞の検査方法